Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
haemophilus b conjugate vaccine diphtheria CRM197 protein conjugate + DPT-IPV
- Development stage
- Unknown
- Lead developer
- Praxis Biologics
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
A dose-unspecified **co-administration vaccine regimen** evaluated in healthy Japanese infants, consisting of the investigational Hib conjugate vaccine MT-2301 and a separate DPT-IPV vaccine. MT-2301 contains *Haemophilus influenzae* type b capsular polyribosylribitol phosphate-derived oligosaccharide conjugated to the nontoxigenic diphtheria-derived carrier protein CRM197; it was administered with DPT-IPV to induce protective immune responses against Hib, diphtheria, pertussis, tetanus, and poliomyelitis. The registered Phase 2 study included distinct MT-2301 low-dose and high-dose arms, so the dose-unspecified input does not identify one unique regimen strength. ([ichgcp.net](https://ichgcp.net/ja/clinical-trials-registry/NCT02140047))
- Other names
- Haemophilus b conjugate vaccine diphteria CRM197 protein conjugate + DPT-IPV
02
Targets
Diphtheria toxinPRP (Haemophilus influenzae type b capsular polyribosylribitol phosphate)TT (Tetanus toxoid)HBEGF (Heparin-binding EGF-like growth factor)
Beyond the preview
Go deeper on haemophilus b conjugate vaccine diphtheria CRM197 protein conjugate + DPT-IPV.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on haemophilus b conjugate vaccine diphtheria CRM197 protein conjugate + DPT-IPV.